#### Bale/Doneen Live Chat Session

11/12/2014 5:30-6:30 pm PST

Bradley Bale, MD



#### Intention of the live chats

- New data and slides
- Discuss "hot" topics
- Case study
- Review upcoming meetings
- Open discussion for remaining



### New Studies??!!!: OMG!



Way too many to discuss. Will concentrate on a few.



### Red Flags





### Male Pattern Baldness is Associated with Increased Risk of Heart Attack

10,885 CAD-free pts.; 20 - 93 yo; 35 yr follow-up

Frontoparietal baldness (FPB) & crown top baldness (CTB) were associated with increased risk of heart attack.

After multiple adjustments both independently predicted risk in men; similar but less significant in women.

40% increased with FPB 13% increased with CTB

Christoffersen, M., et. al. (2014). Visible age-related signs and risk of ischemic heart disease in the general population: a prospective cohort study. *Circulation*, 129(9), 990-998.

Copyright Bale/Doneen Paradigm


# A. Frontoparietal baldness B. Crown top baldness







### I looked in the mirror! Help, Amy!!!







### Polycystic Ovarian Syndrome (PCOS) Associated with Increased Risk of Subclinical ASVD: Background

Prevalence of PCOS 6-10%

PCOS is associated with obesity, IR, DM, and lipid abnormalities.

Some evidence connecting PCOS with subclinical CVD.

### Polycystic Ovarian Disease Associated with Increased Risk of Subclinical ASVD

985 young women followed for 20 yrs.; baseline information on PCOS; at a mean follow-up age of 45yo, assessed for subclinical ASVD with CIMT and CAC.

PCOS defined as having both anovulation and hyperandrogenism.

### Polycystic Ovarian Disease Associated with Increased Risk of Subclinical ASVD

Adjusted for: age, race, education, smoking, menopausal status, BMI, systolic BP, TG, and HOMA-IR.

Women with PCOS were ~ 3X more likely to have CAC OR- 2.70 (95% CI, 1.31–5.60)

Women with PCOS were significantly more likely to have increased bulb and internal carotid-IMT measurements.

### Polycystic Ovarian Disease Associated with Increased Risk of Subclinical ASVD

Study suggests that women in their twenties with PCOS are at increased risk for the development of subclinical CVD.



### **BDM Thoughts**


These young ladies need early assessment of arterial inflammation and potential root causes.

Optimal management should begin at an early age.

This certainly needs to include excellent oral hygiene and routine care in a dental practice.



#### What's the difference?





ASVD disease in the carotid arteries is a major cause of ischemic cerebrovascular events.

Ischemic stroke is more often diagnosed in the left hemisphere than in the right.

This may be due to a higher prevalence, severity, or vulnerability of left carotid artery plaque.

1,414 stroke-free Rotterdam pts; at least one carotid plaque >2.0mm; mean age 72yo; 47% female; MRI of carotids.

MRI determined: prevalence, stenosis, thickness and predominant component (ie, lipid core, intraplaque hemorrhage, calcification, or fibrous tissue).

Purpose: any significant differences by side.

85% of pts had bilateral plaque.


If unilateral, left side was 2X as common as right.

No gender difference in left vs right unilateral plaque, but left sided pts were younger with mean age 68yo vs 71yo.

Thickness was greater in left vs right plaque.

No difference in plaque stenosis or calcification left vs right.

Lipid core and intraplaque hemorrhage were more frequent in left sided plaque.



**Figure 2.** Overall odds ratios (ORs) for the predominance of a specific plaque component in the left carotid artery. The right carotid artery was used as the reference. \**P*<0.05 estimated adjusted for age, sex, and carotid wall thickness.

Plaque prevalence, severity, and composition are not equally distributed among the left and right carotid arteries.

Left-sided plaques have a more vulnerable composition.

Geometric factors: bifurcation angle; direct connection of the left carotid artery to the aortic arch.

Hemodynamic forces: left carotid artery exposed to potentially higher arterial pressures.

Differences found were relatively small and may not explain higher incidence of left hemisphere strokes.

In most people the left hemisphere is dominant for language processing facilitating recognition of an infarct.

Infarcts in the right hemisphere can result in occult cognitive deficit or apraxia.

### Left Internal Carotid Stenosis Associated with Dementia

- Autopsy exam 112 dementia and 577 controls
- Left internal carotid stenosis (≥70%) was associated with dementia
  - OR, 2.30 (95% CI, 1.14–4.74) p=0.02 after multivariate logistic regression models
- Right internal carotid stenosis showed non-significant trend
   OR, 1.96 (95% CI, 0.94–4.08) p=0.07

Suemoto, C. K., et. al. (2011). Atherosclerosis and Dementia: A Cross-Sectional Study With Pathological Analysis of the Carotid Arteries. *Stroke*. doi: 10.1161/strokeaha.111.628156

### Illusion





### Panorex: Left Carotid Calcification



Courtesy Dr. Mike Rogers



### Panorex: Left Carotid Plaque



Soft carotid plaque

Courtesy Dr. Mike Rogers



### Left Internal Carotid Plaque with Thrombus


88 yo male with hx of left hemisphere TIA 1 mo. ago.

Admitted with B-cell lymphoma intestinal infiltration and perforation.

Four days after admission, aphasia and right hemiplegia; diagnosis of left middle cerebral artery stroke.

Delgado, M. G., et. al. (2013). Threatening Internal Carotid Artery Floating Thrombus: Left Middle Cerebral Artery Stroke in a Patient With Lymphoma. *Circulation, 127*(8), e463.

Carotid duplex ultrasonography of a longitudinal section of the left internal carotid artery showed an atherosclerotic carotid plaque (black arrow) with a floating thrombus (white arrow).



Floating thrombus!

Carotid plaque





### Left Internal Carotid Plaque with Thrombus

Anticoagulation treatment with low-molecular-weight heparin was initiated.

Neurological status remained unchanged.

The patient was discharged under anticoagulant treatment.

Later readmitted and died 24 hours later.

Delgado, M. G., et. al. (2013). Threatening Internal Carotid Artery Floating Thrombus: Left Middle Cerebral Artery Stroke in a Patient With Lymphoma. *Circulation, 127*(8), e463.

### **BDM Thoughts**

All carotid plaques must be considered dangerous regardless of 'side'.

Perhaps side does matter in terms of likelihood of events.

Inflammation is the ultimate determinant of risk!



### Inflammation





### 18FDG-PET-CT of Carotid Correlates with Event Risk: Background

High levels of glucose metabolism are seen in tissue with inflammatory activity.

Studies have documented the degree of plaque inflammation depicted by 18FDG uptake is significantly correlated with histopathologic findings.

18FDG-PET-CT can image inflammatory cell activity within the carotid plaque.

Müller, H. F. G., et. al. (2014). 18FDG-PET-CT: An Imaging Biomarker of High-Risk Carotid Plaques. Correlation to Symptoms and Microembolic Signals. *Stroke*. doi: 10.1161/strokeaha.114.006488

Copyright Bale/Doneen Paradigm

### 18FDG-PET-CT of Carotid Correlates with Event Risk: Background

Unstable carotid plaque has a thin fibrous cap and contains large numbers of macrophages and T lymphocytes (inflammation).

Therefore, 18FDG-PET-CT should be able to differentiate which stenotic carotid plaques are generating cerebral symptoms and microemboli.

Examined 123 stenotic carotid plaques derived from 110 pts; 60 symptomatic; 63 asymptomatic.

Target to background ratio (TBR) calculated with maximum uptake of carotid plaque and mean uptake of jugular veins.

Correlated findings with clinical symptoms and presence of microembolic signals (MES) detected by transcranial Doppler.

TBR values were higher in symptomatic compared with asymptomatic (p<0.0018) and in MES+ compared with MES- plaques (p<0.008).

TBR also accurately identified MES+ plaques not only within the symptomatic (11/14, 79%) but also within the asymptomatic group (4/5, 80%).

18FDG-PET-CT accurately detected high-risk carotid plaques.

Inflammatory activity within the carotid plaque was able to discriminate between symptomatic and asymptomatic plaques.

Inflammation was predominant in the soft component of the plaque compared with the calcified one.

Calcification and inflammation rarely overlap.

Remember: a plaque classified as predominantly calcified may still have highly inflamed soft components.

### 18FDG-PET-CT of Carotid Correlates with Event Risk


18FDG-PET-CT as imaging biomarker may be a useful tool in clinical practice.

It could become a part of the standard exam to select pts for intervention or for more aggressive medical treatment.

Müller, H. F. G., et. al. (2014). 18FDG-PET-CT: An Imaging Biomarker of High-Risk Carotid Plaques. Correlation to Symptoms and Microembolic Signals. *Stroke*. doi: 10.1161/strokeaha.114.006488

# 18FDG-PET-CT of Carotid Correlates with Event Risk

Standardized uptake values (SUV) measurement in the region of interest (ROI) of the different plaque components.



Müller, H. F. G., et. al. (2014). 18FDG-PET-CT: An Imaging Biomarker of High-Risk Carotid Plaques. Correlation to Symptoms and Microembolic Signals. *Stroke*. doi: 10.1161/strokeaha.114.006488

Copyright Bale/Doneen Paradigm

### **BDM Thoughts**

Superb study validating inflammation as the trigger of CV events.

Emphasizes the importance of monitoring inflammation in pts with plaque (asymptomatic lesions can be seeding damaging microemboli).

Fortunately, we have less expensive ways to detect inflammation in plaque than PET-CT.




### Inflammatory Message






# The Sun (inflammation) is at the center; not the Earth (lipids). Many scientists for a long time thought it was the other way!



Standard of Care! antiquated





# Carotid Inflammation Predicts Stroke Risk: Background

Microwave radiometry (MWR) noninvasively measures the temperature of carotid plaques.

This temperature ("fire") reflects plaque inflammatory activity.

Higher inflammation is associated with plaque vulnerability.



# Carotid Inflammation Predicts Stroke Risk: Background

Hypothesized that in pts with acute ischemic stroke, culprit carotid arteries will exhibit higher temperature compared with the contralateral carotid arteries.

#### "Carotids causing strokes are on fire!"\*

Toutouzas, K., et. al. (2014). Incremental Predictive Value of Carotid Inflammation in Acute Ischemic Stroke. *Stroke*. doi: 10.1161/strokeaha.114.007526

\*BDM



50 consecutive pts with acute ischemic stroke due to large artery ASVD; carotids evaluated with carotid ultrasound and MWR.

Three segments of 20 mm studied in each carotid artery; middle segment was bifurcation; segment with the highest plaque thickness was target for MWR.

Ipsilateral carotid artery was assigned as culprit.

MWR measurements were performed in both culprit and non-culprit carotid arteries over the segments.

Temperature difference (ΔT) of each carotid artery was assigned as the temperature of the target segment minus the minimal temperature of each carotid.




Culprit carotid arteries had higher  $\Delta T$  compared with asymptomatic carotid arteries.

0.93±0.58 versus 0.58±0.35°C; p<0.001

After adjustment for: sex, age, vascular risk factors, and max plaque thickness, the chance of having a hotter culprit carotid were 6X greater!

OR- 5.94 (95% CI,1.56–22.63) p=0.01





**Figure.** Culprit carotid arteries had higher temperatures compared with nonculprit ones. The bottom of the box represents the first quartile, the top of the box represents the third quartile, and the line in the box represents the median value.



The findings with MWR regarding the inflammatory status of the culprit carotid artery are in accordance with the studies using 18FDG-PET-CT.

Confirms previous studies demonstrating inflammatory activity of plaque significantly interferes progression and destabilization of ASVD.



Diagnostic algorithms to accurately assess ASVD inflammation will increase the accuracy of identifying vulnerable plaque.

A new simple noninvasive method, such as MWR, may be useful in primary and secondary prevention of stroke..



### **BDM Thoughts**

Love this study that literally looks at heat; the F of EDFROG!!!!

Again helps confirm the 'sun' at the center of the ASVD solar system!!

Again, fortunately we have simple serum and urine biomarkers to detect 'fire'! ©




### Fire in the Hole!!!

Hs-CRP
Fibrinogen
Lp-PLA2
MPO
F2 isoprostane
MACR









### Stress Alters Circulatory Nanoparticles-Proteins and mi-RNAs

Heat shock proteins (Hsp) and microRNA (miRNA) are biologically active nanoparticles (40–100 nm) released by cells.

Murine induced stress through the sympathetic nervous system modified Hsp and miRNA levels.

Beninson, L. A., et. al. (2014). Acute Stressor Exposure Modifies Plasma Exosome-Associated Heat Shock Protein 72 (Hsp72) and microRNA (miR-142-5p and miR-203). *PLoS One, 9*(9), e108748. doi: 10.1371/journal.pone.0108748

### What???: Epigenetics





## Psychosocial Issues Alter Epigenetics Which Influence Arterial Inflammation

Psychological stress engenders a pro-inflammatory epigenetic signature, which increases risk for heart attack and stroke.

Hsp can mediate inflammation; miRNAs key regulators of gene expression.

Epigenetics may bridge the psycho-social environment with inflammation and risk for CVD.

Saban, K. L., et. al. (2014). Epigenetics and social context: implications for disparity in cardiovascular disease. *Aging Dis, 5*(5), 346-355.

Guidelines recommend LDL-C as the primary lipid target for recurrent stroke risk reduction.

However, evidence indicates other lipids are superior predictors of stroke.

If that is true they should be therapeutic targets to reduce stroke and recurrent stroke risk.

3,385 recent ischemic stroke (IS) pts.; ~62% male; mean age ~ 66yo; 80% white; baseline lipids with TC/HDL & TG/HDL available; follow-up 2 yrs.

Primary outcome was recurrent IS. (n-272)

Secondary outcome: composite of all MACE. (n-564)

Recurrent stroke was highest in the upper quintile of TG/HDL ratio

HR- 1.68 (95%CI, 1.16-2.45)

MACE was highest in the upper quintile of TG/HDL & TC/HDL ratio

HR- 1.57 (95%CI, 1.21-2.03)

HR- 1.51 (95%CI, 1.17-1.95), respectively

After adjusting for multiple confounders and comparing upper quintile to lower quintile:

Upper quintile TG/HDL ratio had 56% increased risk of IS and 39% increased risk of MACE.

Lowest quintile ≤1.93 Highest quintile >6.22

After adjusting for multiple confounders and comparing upper quintile to lower quintile:

Upper quintile TC/HDL ratio had insignificant 35% increased risk of IS and a significant 45% increased risk of MACE.

Lowest quintile ≤3.50 Highest quintile >5.98

After adjusting for multiple confounders and comparing upper quintile to lower quintile:

LDL/HDL ratio showed no association with risk.

Non-HDL showed no association with risk.

Results suggest that TG/HDL ratio should be a target of therapy to reduce recurrent stroke.


In addition, data suggests in stroke victims TG/HDL and TC/HDL ratios should be targets of therapy to reduce MACE.

### **BDM Thoughts**

- Results consistent with evidence that LDL-C does not predict stroke risk.
- Another study showing serious fallacy with current guidelines recommending LDL-C as primary lipid target of therapy.
- Results consistent with evidence that HDL-C is important in stroke risk as is TG (remnant cholesterol).
- Helps explain why stroke recidivism is shockingly high.
- Helps explain recent results reported in BARI-2D trial with rosiglitazone and stroke.
- Supports BDM goal for TC/HDL as <3.0; TG/HDL goals of</li>
   <3.5 Whites; <3.0 Hispanics; <2.0 Blacks (IR = stroke risk).</li>



### LDL-C Does Not Predict CV Risk!





#### **HDL** is most predictive of stroke

#### Age- and gender-adjusted for all strokes (n=1111)


Variable	Relative risk/standard deviation		95% CI
ApoB/apoA-1	1.14		1.07-1.20
АроВ	1.03		0.97-1.10
ApoA-1	0.84	AMORIS trial: 175000 men and women followed 10.3 yrs.	0.79-0.89
LDL/HDL	1.07		1.03-1.10
TC/HDL	1.08		1.05-1.12
LDL	0.98		0.92-1.05
Non-HDL	1.03		0.96-1.10
HDL cholesterol	0.81		0.77-0.86

The risk of stroke was calculated as a relative risk for 1 standarddeviation unit change (RR/SD). Subjects having the highest apoA-1 and lowest apoB values were used as the reference.

Walldius G et al. *J Intern Med* 3/2006; 259: 259-266.



### HDL is Brain Food





#### HDL & atherosclerotic stroke risk

Each 1 mg/dL increase in HDL yields:

1.9% reduction in stroke risk

Tirschwell DL, et. Al. *Neurology* 2004;63:1868-75



# Elevated Remnant Cholesterol Causes Arterial Inflammation and CHD: Elevated LDL-C Does Not Cause Inflammation

- Remnant cholesterol is the cholesterol content of TG-rich lipoproteins composed of very low-density lipoproteins and IDL in the fasting state, and of these two lipoproteins together with chylomicron remnants in the non-fasting state.
- Remnant cholesterol and TG are two different types of fat and are components of the same lipoproteins, i.e. remnants, and levels of remnant cholesterol and TG are therefore highly correlated (R value=0.96).

Varbo, A., et. al. (2013). Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, While Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease without Inflammation. *Circulation*. doi: 10.1161/CIRCULATIONAHA.113.003008

# Elevated Remnant Cholesterol Causes Arterial Inflammation and CHD: Elevated LDL-C Does Not Cause Inflammation

- A significant causal relationship for CHD remained for remnant cholesterol in subjects without diabetes or obesity.
- The causal relationship for CHD with LDL-C in subjects without diabetes or obesity was not tested!!!

Varbo, A., et. al. (2013). Circulation. doi: 10.1161/CIRCULATIONAHA.113.003008



# Elevated Remnant Cholesterol Causes Arterial Inflammation and CHD: Elevated LDL-C Does Not Cause Inflammation

- LDL particles need to be oxidized before they can be taken up by macrophages, while triglyceride-rich lipoproteins or remnants can be taken up by macrophages without oxidation.
- Residual risk of CHD even with low LDL may be partially explained by the association between non-fasting remnant cholesterol and low-grade inflammation.

Varbo, A., et. al. (2013). Circulation. doi: 10.1161/CIRCULATIONAHA.113.003008



#### AHA 2013 Statistics



#### 23% of strokes are recidivistic!

Every 4 minutes someone dies from a stroke

Go, A. S., et. al. (2013). Heart disease and stroke statistics--2013 update: a report from the American Heart Association. *Circulation*, 127(1), e6-e245.



## Proportion of patients with recurrent stroke within 5 years after first stroke.



Go A et al. Circulation 2014;129:e28-e292



## Insulin Resistance Significantly Increases Ischemic Stroke Risk in Non-diabetic Adults

 1509 multiethnic group free from stroke and DM; followed 8.5 yrs.

 Those in top quartile of IR were 3X greater risk for ischemic stroke

 Independent of traditional risk factors and metabolic syndrome

Arch Neurol. 10/2010;67:1177-1178, 1195-1200



### Pioglitazone Improved CAD via Reducing TG/HDL

- Post hoc analysis 360 subjects in PERISCOPE
- Improved TG/HDL independently predicted change in total atheroma volume p=0.02
- adjusted for: sex, BP, history of PCI, hypercholesterolemia, metformin use, baseline HbA<sub>1C</sub>, and baseline apoA-1.

Nicholls, S. J., et. al. (2011). Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients: Insights From the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) Study. *J Am Coll Cardiol*, *57*(2), 153-159.

#### Rosiglitazone Reduced Stroke Risk 64%

Data from BARI-2D; 748 pts on rosi; 1,363 not on TZD rx; follow-up 4.5 yrs.; evaluated difference in CV outcomes

Stroke HR 0.36 (95% CI 0.16 to 0.86)

Composite death, MI, and stroke HR 0.72 (95% (CI), 0.55 to 0.93)

MI HR 0.77 (95% CI, 0.54 to 1.10)

Bach, R. G., et. al. (2013). Rosiglitazone and Outcomes for Patients with Diabetes and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. *Circulation*. doi: 10.1161/circulationaha.112.000678



# TG/HDL > 3.5 = IR in Caucasians

Ethnicity is Important

Dr. Gerald Reaven 1/2001
 McLaughlin, Reaven, et.al., *Am J Cardiol*. 8/1/2005;96:399-404



### TG/HDL Ratio in Ethnic Groups

Mexican Americans: ≥3.0

Non-Hispanic Blacks: ≥2.0

Chaoyang Li, Earl S. Ford, Yuan-Xiang Meng, Ali H Mokdad, Gerald Reaven *Cardiovascular Diabetology* 2/28/2008, 7:4 doi:10.1186/1475-2840-7-4



#### A1c Misses ~Half of Patients with Pre-diabetes

501 pts screened for pre-diabetes with 75 gram OGTT; also had A1c drawn.

193 pts had IFG and or IGT


A1c missed 90 of the pre-diabetics



Chilelli, N. C., et. al. (2014). Screening with HbA1c identifies only one in two individuals with diagnosis of prediabetes at oral glucose tolerance test: findings in a real-world Caucasian population. *Acta Diabetol*, *51*(5), 875-882.



### **EDFROG IRA**







## RAAS Plus Trimethoprim/Sulfamethoxazole May Kill People

1,027 sudden death cases in ≥66yo pts on RAAS med; occurring within 7 days of exposure to an antibiotic; matched to 3,733 controls (sudden death; on RAAS, but no antibiotic).

Antibiotics were: co-trimoxazole, amoxicillin, ciprofloxacin, norfloxacin, or nitrofurantoin.

Amoxicillin was reference antibiotic.

Fralick, M., et. al. (2014). Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study BMJ 2014;349:g6196 doi: 10.1136/bmj.g6196.

Copyright Bale/Doneen Paradigm

# RAAS Plus Trimethoprim/Sulfamethoxazole Maybe Deadly

Co-trimoxazole associated with increased risk OR-1.38 (95% CI, 1.09 to 1.76)

Ciprofloxacin was also associated with risk OR- 1.29 (95% CI, 1.03 to 1.62)

No increased risk with norfloxacin or nitrofurantoin.

Fralick, M., et. al. (2014). Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study BMJ 2014;349:g6196 doi: 10.1136/bmj.g6196.



# RAAS Plus Trimethoprim/Sulfamethoxazole Maybe Deadly

Trimethoprim has structural and pharmacologic similarities to amiloride.

Trimethoprim blocks the epithelial sodium channel (ENaC) in the distal nephron, impairing renal potassium elimination.

~80% of pts receiving co-trimoxazole develop increases in serum potassium concentrations of at least 0.36 mEq/L and 6% develop frank hyperkalemia.

Fralick, M., et. al. (2014). Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study BMJ 2014;349:g6196 doi: 10.1136/bmj.g6196.

Copyright Bale/Doneen Paradigm

# RAAS Plus Trimethoprim/Sulfamethoxazole Maybe Deadly

Suggest when clinically appropriate, clinicians either choose alternate antibiotics or limit the dose and duration of co-trimoxazole treatment.

When co-trimoxazole is prescribed, close monitoring of serum potassium is advisable in susceptible pts.

Fralick, M., et. al. (2014). Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study BMJ 2014;349:g6196 doi: 10.1136/bmj.g6196.

### **BDM Thoughts**

Reinforces previous warning.

Also makes you wonder about ciprofloxacin.

Remember to monitor K+ closely when initiating therapy with amiloride.



#### Amiloride: K+ Sparing Diuretic

Inhibits of Na+ reabsorption at the distal convoluted tubule, cortical collecting tubule and collecting duct.

This decreases the net negative potential of the tubular lumen reducing both K+ & H- secretion and subsequent excretion.

It is not an aldosterone antagonist and its effects are seen even in the absence of aldosterone.

Usual dose is 5-10mg; may go up to 20mg; comes in 5 mg tablets.

Anna J. Stears, et. al. *Hypertension.* 5/2012;59:934-942



### Potassium Extremely Important in Cardiac Arrhythmias and Sudden Cardiac Death

Incidence of ventricular tachycardia is 3X higher in MI pts with low 'normal' potassium than in pts with a high 'normal' serum potassium.

In pts with known CAD, it is beneficial to maintain plasma potassium levels in the upper normal range.

(4.5-5.0)

Kjeldsen, K. (2010). Hypokalemia and sudden cardiac death. *Exp Clin Cardiol*, *15*(4), e96-99.



#### Want More from Amiloride!!!








# Amiloride Did Not Cause Any Impairment in Glucose Tolerance

- Two double-blind, placebo-controlled, crossover studies; total 78 pts.; outcome was change in 2hr. GTT after 4 wks. rx with Hctz or amiloride
- Thiazide diuretic significantly impaired glucose tolerance; no impairment was seen with K-sparing diuretic
- Substitution or addition of amiloride may be the solution to preventing thiazide-induced diabetes mellitus

Anna J. Stears, et. al. *Hypertension.* 5/2012;59:934-942



#### Metformin: How It Works



"Doc, how is this pill supposed to help me?"

"Sir, it blocks an enzyme that makes the liver put out too much sugar into your blood."

Ferrannini, E. (2014). The Target of Metformin in Type 2 Diabetes. New England Journal of Medicine, 371(16), 1547-1548.

Copyright Bale/Doneen Paradigm

#### Cases !!!





#### 9/2014: 82 yo Caucasian Male

 Known CAD/CT angio; subclinical carotid and femoral ASVD.

 Been plugged into BDM since 2009; cold arteries for several years.

Routine follow-up labs drawn 9/11/2014.



Current meds: (no changes in several years)

Niaspan – 1500 mg

Fish oil - 1 gram

Actos - 45 mg

vit D3 - 5,000 IU

CoQ10 - 200 mg

ASA - 81 mg

Indapamide - 1.25 mg

Dark choc. - 7 grams

Dexilant

Magnesium - 200mg



# 9/2014: 82 yo Caucasian Male Routine follow-up labs drawn 9/11/2014.

Nurse gets results on 9/18:



"This patient is in trouble! You better call him!"



	09	10	11	12	13	5/14	9/11/14
TC	202	152	251	209	205	188	185
TG	59	54	71	65	50	74	58
HDL	97	73	90	90	80	85	89
LDL	93	68	147	106	115	88	84
TC/HDL	2.1	2.1	2.8	2.3	2.6	2.2	2.1
hsCRP	8.0	5.4	1.1	0.9	2.6	0.6	24.5
MACR	6.2	5.2	9.0	3.6		15.6	35.6
PLAC2	146	195	130	126	162	155	185
MPO	1847	221			138	163	283
F2 isopros	1.82	1.08			0.55	0.54	0.27
Pro-BNP	<b>55</b>		35			64	<b>220</b>
	No	GI					9/18
	Niacin	Issue					call
	Lifestyle	fever					Tooth
	issues						Ache!



#### 9/2014: 82 yo Caucasian Male

We have your results back.






"I bet you do not like my results. I have a molar that is hurting and the gum tissue around it seems swollen."



I think you better get it checked now!!!









### They got it out!!





	9/11/14	10/2/14	
TC	185		
TG	58		
HDL	89		
LDL	84		
TC/HDL	2.1		
hsCRP	24.5	0.6	
MACR	35.6	7.7	
PLAC2	185	167	
MPO	283	134	
F2 isopros	0.27		
Pro-BNP	220	41	
	9/18	9/24	
	Tooth	Tooth extract.	
	Ache!		



### Close call !!!





# New Patient Requiring Extensive Restorative Care

- Medical issues affecting dental decisions:
- 65 y.o. male, 5,9", 190 lbs, waist 38"
- Presents for extensive dental restorative care
- Has history of periodontal disease but current disease is stable (no bleeding on periodontal chart)
- Has a structural fracture of upper right front tooth that cannot be saved.
- Two stents placed at 54 years old. No evidence of advanced lipid testing.
- No evidence by history that he is doing anything differently now than he was before stent placement.
- Concern as a dental provider is how inflamed is he and is he stable enough for us to begin invasive work?











# Asked for Any Current Labs

Recommended collecting a more comprehensive collection of information

	5/15/2014 0845	
CHEMISTRY PANELS		
Sodium	140	m 'm to tot m' : 1 :
Potassium	4.0	
Chloride	100	
Carbon Dioxide (CO2)	32	<b>!</b> ^
Anion Gap	8	
Glucose	93 *	
Blood Urea Nitroge	23	
Creatinine	0.69	
Calcium	9.8	
Protein Total	6.5	
Albumin	4.3	The statement of the
Globulin	2.2	
Albumin/Globulin R	2.0	
Alkaline Phosphata	79	
Aspartate Aminotra	32	
Alanine Aminotrans	39	
Bilirubin Total	0.7	CONTRACTOR OF THE CONTRACTOR O
GFR Non African Am	115	
GFR African American	139 *	,
ENDOCRINE	War market	1.79.000
Free FT3	3.5	1 MGGG
Free FT4	1.3	
TSH	1.72	
LIPIDS		
Cholesterol	155 *	
Triglycerides	103 ×	
HDL Cholesterol	50 ×	
LDL Cholesterol, C	84 ×	
Non-HDL Cholestero	105	100 00 00 00 00 00 00 00 00 00 00 00 00
Cholesterol/HDL Ratio	3.1*	March Ca. Nat.
TUMOR MARKERS		ale Soneen
PSA		METHOD

#### 3rd PARTY REQUISITION FORM



Know your risk.

#### INSTRUCTIONS

- Please complete all highlighted areas in their entirety.
   Please provide all specimen information (draw date/time).

6701 Carnegie Avenue | Suite 500 | Cleveland, Ohio 44103 p 866.358.9828 | f 866.869.0148

PRACTITIONER INFORMAT	TION		PATIENT INFORMATI	ON			
Client ID			DOB		□ Male □ Fem	ale	
Practitioner ID			Last Name		- Ironing and a second		
Practice Name			First Name		Middle Initial		
Practitioner Name			AND THE PROPERTY OF THE PROPER			le.	
NPI			Ht. Wt.	ВМІ	Fasting? Yes	722	
Address			Race American Indian/Alaska White/Caucasian (Non-i	Villa	☐ Asian ☐ Black/African-Amer ☐ Hispanic/Latino ☐ Other	ican	
State		ZIP	Patient Demographics Sheet Attached				
one Fax			Address				
TEST MENU (Please fill in box cor	npletely)		City	Stat	te ZIP		
The same of the sa	THYROID FUNCT	ION	Phone				
Myeloperoxidase (83876)	☐ T4, Free (B4439)		Other Patient ID		Last Four Digits of SSN	1	
ALp-PLA <sub>2</sub> (The PLAC* Test) (83698) Lingh-Sensitivity CRP (hs-CRP) (86141)	☐ T4, Total (84436) ☐ T3, Free (84481)		PILL INC INCORMATIO	NAME OF	en e	45.5	
High-Sensitivity CRP (hs-CRP) (88141)  Microalbumin/Creat Ratio (82043/82570)  Oxidized LDL (83516)  F <sub>2</sub> -Isoprostanes/Creat Ratio (83789/82570)	☐ T3, Total (84450) ☐ TSH (84443)	ree if indicated (84439)	COPY OF FRONT & BACK OF MUST BE ATTACHED TO THIS	PATIENT	NAME AND ADDRESS OF THE OWNER, WHEN PERSON ADDRESS OF THE OWNER, WHEN PERSON AND ADDRESS OF THE OWNER, WHEN	E CARD	
OTHER INFLAMMATION TESTS		ree if indicated (84481)	Note: A patient approved Medica		orm required for AnnE MTHER	v CYP2C19	
A Galectin-3 (82777)	ANEMIA/IRON M  Ferritin (82728)	ETABOLISM	and all V70 diagnostic cod	es; atherv	vise testing will not be performe	d,	
Fibrinogen Mass (85385) CHomocysteine (83090)	☐ Iron (83540)		Medicare#				
LIPIDS	☐ Serum Iron & IBC (83540/83550) ☐ Foliate (82746)		Medicare HMO Provider#				
Standard Lipid Panel (Includes non-HDL cholesterol) (80061)	☐ RBC Folate (8274) ☐ Vitamin B12 (8260)		Insurance Provider:		400		
☐ If TGs >400 mg/dL reflex to a Direct LDL (8372) ✓ ApoB (82172)	CANCER		Policy ID#		A TO		
☐ ApoA1 (82172) ☐ sdLDL (83701)	PSA, Total (84153	Free if indictated (84154)	Patient Relation: Self	Spot	use Dependent		
Lp(a) (83695)	PSA, Total (G0100	( Medicare)	Patient Self-Pay: By che	cking the	box, the patient will receive a d	iroct hill	
☐ HDL2b (82664)  NMR LipoProfile* with Lipids (83704/60061)*	☐ Reflex to PSA,	Free if indicated (84154)	T ameni san rayrayan	oning tire	y oraș, uno panorii mii recurre a c	moot biii.	
NMR LipoProfile* with Lipids (83704/80061)*	PLATELET FUNC		DIAGNOSIS (ICD-9 Code)				
METABOLIC  Glucose (82947)	GENETICS		☐ Acquired Hypothyroidism, spec.	244.8	Other Malaise and Fatigue	780.79	
Minsulin (83525)	☐,CYP2C19 (81225)		☐ Acquired Hypothyroidism, unspec.	244,9	Shortness of Breath	786.05	
<ul> <li>Reflex to Adiponectin if indicated (83516)</li> </ul>	ApoE (81401)  MTHFR (81291)		☐ Diabetes Type II	250.00	☐ Impaired Fasting Glucose	790.21	
S OGTT (82951)  GLYCOMARK® (84378)		D 70 JF	Diabetes Type II, uncontrolled	250.02 268.9	Impaired Glucose Tolerance	790.22	
TSCHDA1c (83036)	ROUTINE PANEL  Basic Metabolic P		☐ Vitamin D deficiency ☐ Pure Hypercholasterplemia	272.0	☐ Abnormal Chemistry ☐ Abnormal Clinical Findings	790.6 796.4	
✓ □ Reflex to GLYCoMARK® if indicated (84378)	Comprehensive M		Pure Hyperglyceridemia	272.1	☐ Family Hx of CVD	V17.3	
Adiponectin (83516)	☐ Hepatic Function	Panel (80076)	Mixed Hyperlipidemia	272.2	☐ Family Hx of Other CVDs	V17,49	
☐ Fructosamine (82985) ☐ C-Peptide (84681)	☐ Renal Function Panel (80069)		Unspec. Hyperlipidemia	272.4	Family Hx of Diabetes	V18.0	
☐ Cystatin C (82610)	☐ Electrolyte Panel (	50051)	☐ Metabolic Syndrome	277.7	☐ Long-term Use of Aspirin	V58,66	
CARDIAC	STANDARD LAB	DRATORY TESTS	Unspec. Iron deficiency anemia	280.9	☐ Long-term Medication Use	V58.69	
NT-proBNP (83880)*	CBC (85027)*	025)*	☐ Hypertension, malignant	401.0	☐ PSA Screening	V76,44	
☐ Creatine Kinase (82550)	☐ Urinalysis (81001)		Hypertension, benign	401,1	Other	_	
VITAMINS/SUPPLEMENTS	☐ Uric Acid (84550)		Hypertension, unspec.  intermediate Coronary Syndrome	401.9	Other	-	
SCoenzyme Q10 (83789)*	CLEVELAND CLINIC	WELLNESS PROGRAMS	Coronary Atherosclerosis of unspec		☐ Other		
Vitamin D, 25 OH (82306)	☐ Goff Foods for Yo		type of vessel, native or graft	414.00	☐ Other		
Ustamin D2/D3 (82306)	☐ Stress Free Now		☐ Coronary Atherosclerosis, native		Other		
FATTY ACIDS	☐ Go!* to Sleep		coronary artery	414.01	☐ Other		
☐ OmegaCheck <sup>™</sup> (B2541)	OTHER		☐ Congestive heart failure, unspec.	428.0	Other		
HORMONES	0		Note: The provided ICD-9 codes are listed a that best describes the reason for performing				
☐ Testosterone, Total (84403) ☐ Estradiol (82670)	0		practitioners must provide the 4th or 5th ICD-9	digit as appro	opriate. Only tests that are medically reasonal	sie and necessary	
☐ FSH (83001)			for the diagnosis or treatment of a Medicare in takes the position that a physician who orders	r Medicaid p medically on	sitient will be reimbursed. The Office of the in recessary tests for Mertinary or Martine's ed	nspector General	
Luteinizing Hormone (83002)	<u></u>		be subject to civil penalties under the False C	laims Act.	,		
☐ Progesterone (54144)	0		C				
			COMMENTS:				
	0		II.				
	<u> </u>		H				
			ll				




#### **Current Meds**

Multi vitamin & minerals AM		
Fish oil 1000mg pm		
Saw Palmetto+ 160 mg AM		
Coenzyne Q10 100 mg AM		
DMAE 500mg AM		
Alpha Lipoic Acid 100 mg AM		
Biotin 5 mg AM		
B12 1000mcg AM		
Slo Niacin 500mg AM		



#### **Periodontal Chart**



**CAL 1-3** 

Teeth

Fractured tooth

10/9/2014

#### **Desired Information**

- Oral DNA
- Cone Beam Image
- Inflammatory Biomarkers to determine stability
- Advanced Lipids
- Bale/Doneen Method Info



## Oral DNA Pending



### Cone Beam Image Report

Images provided: Cone Beam CT images in the bone window. Axial, coronal and sagittal planes. FOV:

<u>Clinical Info:</u> Implant analysis requested. Relevant History: Implants planned Client Notes: Implants planned

#### **Diagnostic Objectives:**

- 1. Implant Planned
- 2. Rule Out Pathology

#### **Findings:**

Maxilla: no abnormalities detected

Sinuses: no abnormalities detected, the right and left osteomeatal complexes were patent.


Nasal Cavity: a mild deviation the nasal septum was noted.

Mandible: no abnormalities detected
Air Space: no abnormalities detected
TMJs: no abnormalities detected

Other findings: 1) Curvilinear 200 of increased density were noted lateral to the pituitary fossa and within the lower neck in areas anatom any associated with the carotid arteries; these areas appear to be consistent with calcification carotid artery. 2) sclerosis and small osteophytes were noted C-1 C-2 cervical vertebra. 3) An ovoid area of increased density was noted in the midline of the middle cranial fossa in an area associated with the pineal gland. The area appears consistent with calcification of the pineal gland. The Dental findings: cross-sections illustrating several dental findings have been provided below.



The following are selected images from the volume illustrating major findings



Reconstructed panoramic radiograph



Curvilinear areas of increased density were noted lateral to the pituitary fossa and within the lower neck in areas anatomically associated with the carotid arteries; these areas appear to be consistent with calcification carotid artery.

	In Range	Out of Range	Flag**	Relative Risk	Reference	Units	Previous Result	Date
	DESCRIPTION OF THE PROPERTY OF			KISK	Range		Kesuit	
Myeloperoxidase (5)	276			LOW	<420	pmoVL		
Based on a recent study of a high risk punderwent elective diagnostic coronary off of <420 pmoVL defines an "apparent a population at intermediate risk for a crest of the coronary off of the crest of the coronary of the crest of the creek of the crest	angiography1, Cle kly heakhy" populat ardiovascular even J Cardiol, 111:465	veland Heart Lab ha ion at low risk for a 1, and >=480 pmol/i -70, 2013).	es defined cardiovas	the following cular event,	cut-offs for MP 420-479 pmol/L	defines		
Lp-PLA <sub>2</sub> (The PLAC <sup>®</sup> Test)	146			LOW	≤ 200	n <i>gl</i> mL		
High-sensitivity CRP	0.8			LOW	<1.0	mg/L		
Microsibumin/Creatinine ratio	See Below				<30.0	mg/g		
Microsibumin  Creatinine, Urine	<3.0 70.4				20.0-300.0	mg/L mg/dL		
nephropathy (1). A 3-fold increase in C women with values >= 7.5 mg/g in the F et al. Circulation 2006;112:969).	VD has been found ramingham Heart S	in men with Micros Study (2), (Reference	ibumin/Cr ces: 1. Dia	eatinine ratio betes Care 2	es >= 3.9 mg/g ar 2011;34:533A; 2	. Arnlov		
					20.0.200.0			
Crewnine, Units	70.4	<b>1</b>			20.0-300.0	mgoc		
OXLDL	34			LOW	<60	U/L		
Based on a recent study of an 'apparent been defined for OxLOL: A cut-off of <6 a range of 80 to 69 U/L defines a popul high relative risk (3.5-fold). (Reference: F <sub>2</sub> -Isoprostane/Creatinine Ratio <sup>(5)</sup>	0 U/L defines a polation with a modera 1-Holvoet et al. JA 0.57	pulation with a low rate relative risk (2.8	fold) and	k of developing	ng metabolic sy	ndrome,		
F <sub>Z</sub> -Isoprostane	0.40		1			ng/mL		
Creatnine, Urine	70.4		######################################		20.0-300.0	rrig/dl.		
Homocysteine	7.7				<15.0	umol/L		
LIPIDS	Low and the state of the second	ROBERT STATE OF THE PARTY OF TH						

Lp(a)

HIGH

<30

mg/dL

	In Range	Out of Range	Flag**	Relative Risk	Reference Range	Units	Previous Result	Date
NMR LIPOPROFILE							,	
LDL Particle Number (LPO)		1463		HIGH	<1000	nmol/L		
LDL Cholesterol, Calculated (LIPO)	75			LOW	<100	mg/dL		
LDL-C is inaccurate if patient is nonfast	CONTROL OF THE PARTY OF THE PAR	The second	to the same here.	The little was a second	ball med I among select	.0		
HDL-C (Lipo)	56	1		FOM	≥40	mg/dL		
Triglycerides (LIPO)		227	e nec en,	HIGH	<150	mg/dL	0	
Cholesterol, Total (LIPO)	176			LOW	<200	mg/dL		
HDL-Particle Number (LPO)	49.7			LOW	≥30.5	umoVL		
Small LDL-Particle Number (LPO)		1084		HIGH	<u>≤</u> 527	nmoVL		
LDL Size (LPO)		20.1		HIGH	> 20.5	nm		
Large VLDL-P (LIPO)		11.0		HIGH	≤2.7	nmol/L		
Large HOL-P (LIPO)		3.3		HIGH	≥4.8	umoVL		
VLDL Size (LIPO)		54.1		HIGH	≤46.6	nm		
Small LDL-P, LDL Particle Size, Lurge thave been validated by LipoScience bu established.	IDL-P, Large VLD not cleared by US	L-P VLDL Size, HD 5 FDA; the dinical u	L Size, Hi tility of the	OL Particle, a ese test result	nd LP-IR Score is has not been	fully		
HDL Size (LIPO)		8.6		HIGH	≥9.2	nm		
LP-IR Score (LIPO)		81		HIGH	≤45			

	In Range	Out of Range	Fizg**	Relative Risk	Reference/ Optimal Range	Units	Previous Result	Date
OXLDL	34			LOW	<60	UA		
Based on a recent study of an been defined for OxLDL: A cul-	off of sent Itt dafnes a non	ulation with a law	adaption sin	h all dame land	a in an article will be seen			
a range of 60 to 69 U/L defines high relative risk (3.5-fold). (Re	a population with a moderat	e relative risk (2.8	fold) and	>=70 U/L de	ines a populatio	n with a		
s range of 60 to 69 U/L defines high relative risk (3.5-fold), (Re ructosamine <sup>(CCF</sup> )	e a population with a moderat ference: 1-Holvoet et al. JAN 228	e relative risk (2.8 AA. 2006; 299; 221	fold) and 37-2293.)	>=70 U/L de	ines a populate	n with a		
a range of 60 to 69 U/L defines	is a population with a moderate ference: 1-Holvoet et al. JAN 228  228  Init: umol/L (NOTE) INTERPIREMENTAL STATE PROPERTY INTERPIREMENT STATE PROPERTY INTERPIREMENT STATE PROPERTY INTERPIREMENT STATE PROPERTY INTERPI	RETIVE INFORMA fuctosamine result	fold) and 37-2293 )	>=70 U/L de	fines a population	n with a		



VITAMINS/SUPPLEMENTS							
	In Range	Out of Range	Flag**	Relative Risk	Reference Range	Units	Previous Result
Coenzyme Q10 (1)	3.02			LOW		ug/mL	
Population reference range: 0.36 to 1.5 show an anti-hypertensive effect.	9 ug/mL. Studies h	nve suggested that	serum lev	rela of Coenz	yme 010 at > 2	.0 ug/mL	
Vitamin D, 25-Hydroxy by LC-MS/ MS (4)	42.1			LOW	30.0-80.0	ng/mL	

Incidence of 25-OH Vitamin D toxicity increases when total Vitamin D is above 100 rig/mt, and the majority of individuals with toxicity have total Vitamin D levels at > 150 rig/mt. (Reference; Jones G Am J Clin Nutr 2008,88:5825).

	In Range	Out of Range	Flag**	Relative Risk	Opti mal	Units	Previous Result	Date
OmegaCheck <sup>1</sup> * Whole Blood: EPA+DPA+DHA) <sup>(3</sup>	5.4			LOW	≥5,5	% by wi		
The risk entegories for DmegaChock reference population. Consumption of DHA or DPA) may increase onlega-3 due to cardiovascular disease.* The timited to 3 g/day or loss of EPA and daily dosage of 1 gram of EPA and D or al. N Engl J Med. 2001; 346: 1113-	I foods rich in ornegat falty acid levels mea atality of the scientifi DHA, there is no sign HA lowers the circula	i-3 fatty acids of sup- sourced by OmegaCh c evidence demons inficant risk for incre- sting trigfycerides by	pplements neck, and trates that seed blee	containing on decrease the when consun- ding time bey	nega-3 fatty at risk of sudden aption of fish o and the norma	death death its is trange. A		
Arachidonic Acid/EPA Ralio		7.7	n		<5.0	ļ	a a comment	
Omega-6/Omega-3 Ratio		5.2	н		<4.5			
Omega-3 total	6.4					% by wt		
EPA		1.5	L		>2.0	% by wt		
OPA	1.5				>1.0	% by wt		
DHA		3.4	L		>4.0	% by wt		
Omega-6 fotal	33.00					% by wt		
	ber of omega-6 fatty	acids with AA and	LA being !	he two most a	bundant form			
Cleveland HeartLab measures a num reported.						NYTES NEW YORK	4	
		11.5	н		<9.0	% by wt		

	Genotype	Risk	Interpretation
MTHFR <sup>(2)</sup>	577TT, 1288AA	нідн	This patient displays the homozygous mutation at position 677 (T1) and no mutation at position 1298 (AA) of MTHFR. Homozygous mutations at 677 (TT) and no mutation at position 1298 (AA) are associated with greatly decreased MTHFR activity, high levels of homocysteine and increased risk for coronary artery disease and venous thromboxis, particularly in the setting of low foliate status.



Date

#### OUT OF RANGE RESULTS SUMMARY

	Result	Flag**	Relative Risk	Reference/ Optimal Range	Units
LIPIDS					
Lp(a)	131		HIGH	<30	mg/dL
LOL Particle Number	1463		HIGH	<1000	nmol/L
Triglycerides	227		HIGH	<150	mg/dL
Small LDL-Particle Number	1084		HIGH	≤527	nmel/L
LDL Size	20.1		HIGH	> 20.5	om
Large VLDL-P	11,0		HIGH	≤2.7	nmal/L
Large HDL-P	3.3		HIGH	≥4.8	umol/L
VLDL Size	54.1		HIGH	≤46.6	nm
HDL Size	8.6		HIGH	≥9.2	nm
LP-IR Score	81		HIGH	≤45	
FATTY ACIDS					
Arachidonic Acid/EPA Ratio	7.7	н		<5.0	
Omega-6/Omega-3 Ratio	5.2	н		<4.5	Security of the second
EPA	1.5	L.	11.33.17	>2.0	% by wt
DHA	3.4	L		>4.0	% by wt
Arachidonic Acid	11.5	н		<9.0	% by wt

Previous Result	Date
- 11/2 - 2 mil (= 11 )	
1410 001 001 141 1	

Date		10.744	Date					
Age								_
WT/Waist/ B/P								
Last Flu/pnm Vaccine								
INFLAMMATION	Ok Car Dental		OGTT		1 hour and 2 hour		П	
hs CRP	<1.0 mg/L	.8	Vit D		>30 sufficient	42.1		
Myeloperoxidase	<420 pmol/L	276	Potassiu	m	4.6 - 5.0	000a		
Lp-PLA2 PLAC Test	≤ 200 ng/mL	146	Alt/Ast		0-55 U/L / AST 5-34 U/L			
Urinary MicroAlb/Creat	<3.5 mg/g M <7.5 W	-	CBC					
F2-Isprostanes/Creat	<0.86 ng/mg	.57	CoQ10		.36-1.59 μg/ml	3.02		
Oxidized LDL	<45 U/L	34	TSH					
Bilirubin	>0.8 mg/dL	.7	Omega 3	3		6.4		
Fibrinogen	175-400 mg/dL		Aspirin I	Response	<1500			
			Perio Di		Active or Stable			
LIPIDS								
Total Cholesterol	<200 mg/dL	176						
Triglycerides =VLDL + 1	DL <150 mg/dL 🖈	227	GENET	ICS 40% of Risk			0.0	
LDL-C	<100 mg/dL	75	Apo E					
HDL-C	>50 mg/dL W >40 mg/dL M	58	9p21					
Non-HDL Cholesterol	<130 mg/dL		KIF6					
Аро В	<100 mg/dL		IL-Beta					
Apo A	>130 mg/dL W >120 mg/dL M		Haptogle	obin				
Apo B/Apo A1 Ratio	<0.70 W <0.75 M		CYP2C1	19 Plavix				
sdLDL	<40.0 mg/dL		4q25 At	rial Fibriliation Risk				
Lp (a)	<30 mg/dL ★	131	CYPIA	2 Caffiene Metabolism				
HDL2b (%)	>25 %		TCF7L2	Diabetes and IR Risk				
Alc	≤5.6 %		MTHFR		3	677777 125844	High Past	k
TG/HDL IR Indicator	3.5mg/dL \$1 Shallbe ≤ 45	3.9/	OTHER	R IMAGING +/- Arter	iosclerosis			
OTHER ADVANCED			VH-IVU	And the second s	********			
			Panorex	21				
NT pro-BNP	And the second s		Cone Be	eam Results				
NT pro-BNP hs Cardiac Troponin	>7.9							-
NT pro-BNP hs Cardiac Troponin Galectin 3	>7.9		CACS					

Has purticle # and size issues managed by Dr. Itahn


#### Discussion

- Inflammation ok
- Lifestyle diet, sleep, exercise
- Lipid Management multiple adjustments on BD Method

 Ok to start dental treatment and work with medical team on CVD management



## The carotid arteries serve as a window to systemic atherosclerosis



Willeit, K., et. al. (Sept 12, 2013). Carotid Atherosclerosis and Incident Atrial Fibrillation. *Arteriosclerosis, Thrombosis, and Vascular Biology*. doi: 10.1161/atvbaha.113.302272



## IMT of Carotid (CIMT) American Heart Association


safe, non-invasive, inexpensive, valid and reliable



AHA Expert Panel Statement of Prevention V

Conference – Circulation 2000











Moss Freedman

## Gout Increases the Likelihood of New Onset Diabetes

35,339 gout pts; 72% men; mean age 63 yo; gender, age, BMI matched with 5 non-gout pts; investigated incidence of new onset DM over 1000 person-years.

Adjusted for: smoking, alcohol, physician visits, comorbidities and medication use.

Rho, Y. H., et. al. (2014). Independent impact of gout on the risk of diabetes mellitus among women and men: a population-based, BMI-matched cohort study. *Annals of the Rheumatic Diseases*, doi: 10.1136/annrheumdis-2014-205827



#### Gout is Associated with Increased CV Risk

5,926 subjects; 25 to 74 yo; followed 16 yrs.

For each 59.48-µmol/L increase in uric acid level, ischemic heart disease mortality increased 17% in men and 30% in women.

Adjusted for: age, race, BMI, smoking, alcohol, cholesterol, BP, DM and diuretic use.

Fang, J., & Alderman, M. H. (2000). Serum uric acid and cardiovascular mortality: The nhanes i epidemiologic follow-up study, 1971-1992. *JAMA*, 283(18), 2404-2410.



## TG/HDL > 3.5 = IR in Caucasians

### Ethnicity is Important

Needs OGTT to define beta cell function loss

Dr. Gerald Reaven 1/2001

McLaughlin, Reaven, et.al., *Am J Cardiol*. 8/1/2005;96:399-404



### Who is the Worst Hombre?





### Lipo (a) Causes Heart Attacks

Copenhagen Data: >41,000 subjects over 13 years, 2800 MI's

Looked at risk of MI from lipo (a) levels by assessing the levels genetically

Consistent increase in MI risk with higher lipo (a) levels

Risk starts around 40-50 mg/L; each doubling of the level increases the risk about 20%

Dr Pia R Kamstrup, PR, et. Al., JAMA 6/10/09



## Lipo (a) Continues to Drive CV Risk Despite Statin Therapy

Baseline and on-statin Lp(a) concentrations were associated with residual risk of CVD independent of other risk factors, including LDL cholesterol.



### **European Atherosclerosis Society**

Recommend screening for lipo (a)

Treat if levels over 50 mg/dL

Advise 1 to 3 g of niacin daily

Would d/c Zetia and increase a good OTC niacin (Endur-acin)

Nordestgaard, B. G., et. al. (2010). Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J.* doi: 10.1093/eurheartj/ehq386



## Ezetimibe Yields Paradoxical Results with CIMT: Possible Mechanisms

- Ezetimibe predominately inhibits the scavenger receptor
   B1, involved in intracellular translocation of cholesterol
- This receptor binds to the ligand apoprotein A1, the principal apoprotein component of HDL-C in the process of reverse cholesterol transport
- Ezetimibe is also known to cause transcriptional downregulation of key lipid transport proteins including the ATP binding cassette transporter (ABCA1) and SRB1.

Taylor, A. J., et. al. *European Heart Journal* doi:10.1093/eurheartj/ehs105




## Ezetimibe Yields Paradoxical Results with CIMT: Possible Mechanisms

- Recent studies also suggest that the effect on the lipid particle profile is an absolute or relative increase in the proportion of small dense LDL-C.
- Endothelial function: 8 of 11 trials showed blunting of improvement combined with statin; 2 largest trials showed no effect as mono-rx despite LDL reduction = statin



#### ASCOT Pre-specified Subgroups: Primary End Point





## Atorvastatin Increases Insulin Resistance

 Randomized, blinded, placebo-controlled; 213 subjects; placebo or atorva 10,20,40,80mg; two months

Atorva significantly increased fasting insulin (mean changes: 25%, 42%, 31%, and 45%, respectively) and A1c (2%, 5%, 5%, and 5%, respectively); compared baseline p<0.05 or placebo (p=0.009 for insulin and p=0.008 for A1c</p>


Would switch to Crestor, if KIF6 +, could consider pravastatin.

Koh, K. et al., J Am Coll Cardiol 9/2010;55:1209-16



# Stroke results HOPE (ramipril) 32% EUROPA (perindipril): NS 6%


#### ■ Placebo ■ ACE inhibitor



HOPE NNT 4.5yrs to prevent one major CV event = 26 EUROPA NNT 4 yrs. to prevent one major CV event = 50

Male Oneen

## HOPE: Ramipril and the Risk of Type 2 Diabetes



Days of Follow-up


Lale

Copyright Bale/Doneen Paradigm

Circulation.8/2005;112:1339-1346.

#### Percent Change in Adiponectin Levels and Percent Change in Insulin Sensitivity

50 pts. With DM



## The Direct Effects of the ACE Inhibitors, on Isolated Human Pancreatic Islets

- RAS molecules are present in human islets and their expression is sensitive to glucose concentration
- ACE inhibitors protect human islets from glucotoxicity

Lupi, R. et al., Eur J Endocrinol 2006;154:355-61.



## Potassium Extremely Important in Cardiac Arrhythmias and Sudden Cardiac Death

Incidence of ventricular tachycardia is 3X higher in MI pts with low 'normal' potassium than in pts with a high 'normal' serum potassium.

In pts with known CAD, it is beneficial to maintain plasma potassium levels in the upper normal range.

4.6-5.0

Kjeldsen, K. (2010). Hypokalemia and sudden cardiac death. *Exp Clin Cardiol*, *15*(4), e96-99.



#### Foods High in K+

- Sweet Potato 1 cup cooked 950 mg potassium
- Butternut squash 1 cup cooked 582 mg potassium
- Figs 4 large 541 mg potassium
- Cantaloupe 1 cup 494 mg potassium
- Lentils 1/2 cup cooked 475 mg potassium
- Avocado 1/2 medium 439 mg potassium
- Bananas 1 medium 422 mg potassium
- Spinach 2 cups raw 334 mg potassium
- Blackberries 1 cup 282 mg potassium
- Strawberries 1 cup 252 mg potassium
- Almonds 1 ounce raw 198 mg potassium



### Amiloride: K+ Sparing Diuretic

Inhibits of Na+ reabsorption at the distal convoluted tubule, cortical collecting tubule and collecting duct.

This decreases the net negative potential of the tubular lumen reducing both K+ & H- secretion and subsequent excretion.

It is not an aldosterone antagonist and its effects are seen even in the absence of aldosterone.

Usual dose is 5-10mg; may go up to 20mg; comes in 5 mg tablets.

Anna J. Stears, et. al. *Hypertension.* 5/2012;59:934-942



## Amiloride Did Not Cause Any Impairment in Glucose Tolerance

- Two double-blind, placebo-controlled, crossover studies; total 78 pts.; outcome was change in 2hr. GTT after 4 wks. rx with Hctz or amiloride
- Thiazide diuretic significantly impaired glucose tolerance; no impairment was seen with K-sparing diuretic
- Substitution or addition of amiloride may be the solution to preventing thiazide-induced diabetes mellitus

Anna J. Stears, et. al. *Hypertension.* 5/2012;59:934-942



## Lifestyle to Prevent Myocardial Infarction (MI) in Men

20,721 healthy men 45-79 yo; followed 11 yrs.; 1,361 incident cases of MI.

Evaluated impact of diet, moderate alcohol, no smoking, physical activity and waist on risk of MI.

Akesson, A., et. al. (2014). Low-Risk Diet and Lifestyle Habits in the Primary Prevention of Myocardial Infarction in Men: A Population-Based Prospective Cohort Study. *J Am Coll Cardiol, 64*(13), 1299-1306.



#### Lifestyle to Prevent Heart Attacks

Having all 5 factors optimized compared with none: RR of MI -0.14 (95% CI: 0.04 to 0.43)

Optimization of these healthy behaviors could prevent 79% (95% CI: 34% to 93%) of the MIs in men!

Akesson, A., et. al. (2014). J Am Coll Cardiol, 64(13), 1299-1306.



### Lifestyle Has Huge Impact on Stroke Risk

23,927 subjects; followed 12.7 yrs.; 195 women (73% IS) and 356 (78% IS) men had incident stroke.

Evaluated impact of obesity, smoking, alcohol consumption, diet, and physical inactivity on stroke risk.

38% of strokes were estimated as preventable with adherence to a healthy lifestyle.

Tikk, K., et. al. (2014). Primary Preventive Potential for Stroke by Avoidance of Major Lifestyle Risk Factors: The European Prospective Investigation Into Cancer and Nutrition-Heidelberg Cohort. *Stroke*, *45*(7), 2041-2046.

Copyright Bale/Doneen Paradigm

#### **Exercise to Prevent Diabetes**

Burning an extra 500 kcal/wk can reduce the risk of developing type 2 diabetes by 6%.

Helmrich SP, et al. N Engl J Med. 1991; 325:147-152



# Improving Fitness Level Reduces Type 2 DM Incidence up to 70%

- 4,187 healthy men; fitness assessed 4X over 7 yrs. (1979-1985)
- HR for DM comparing lowest to highest fitness trend quartile, after adjustment for: age, initial fitness, BMI, syst BP, smoking, alcohol and Famhx DM
   0.33 (95% CI- 0.21-0.50)

Sawasa, S. S., PhD, et. al. Diabetes Care 6/2010, Vol. 33, No. 6:1353-1357



# Interval Training: Beneficial for Metabolic Syndrome (MS)

- 32 MS subjects; three groups: interval training (IT), continuous moderate exercise (CME) or control
- IT: warm up 10 mins. at 70% MHR, four 4-min. sessions 90% MHR, with 3 min. recovery periods at 70% MHR, 5 min. cool-down, 3X/wk for 16 wks
- CME 45 mins. at 70% MHR, 3X/wk for 16 wks
- IT > insulin sensitivity; HDL levels increased 25%; lower FBG; decrease waist

Tjonnas AE, Lee SJ, Rogonmo O, et al. *Circulation*. 8/1/2008;doi:10.1161/circulationaha.108.772822.



### Lifestyle to Prevent Heart Attacks: diet

Healthy foods included: fruits, vegetables, legumes, nuts, reduced-fat dairy products, whole grains, and fish.



Unhealthy foods included: red and processed meat, fried potatoes, solid fats, full-fat cheese, white bread, refined cereals, and various sweets.

Akesson, A., et. al. (2014). J Am Coll Cardiol, 64(13), 1299-1306.



# Cinnamon Reuces Glucose and Improves Lipids

- Meta-analysis of 10 RCTs; 543 diabetic pts; cinnamon 120 mg/d to 6 g/d for 4 to 18 wks
- Cinnamon showed statistically significant decrease in levels of fasting plasma glucose, TC, LDL-C, TG and increased HDL-C.

Allen, R. W., et. al. (2013). Cinnamon Use in Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis. *Ann Fam Med*, 11(5), 452-459.




## Mediterranean Diet (MD) Modulates Glycemic and Stroke Risk Generated by TCF7L2 Gene

- 7,018 pts. all genotyped for TCF7L2; 14.2% were (+)-TT; randomized 3 dietary arms (2- MD); followed 4.8 yrs; end points glycemic levels, lipids and CV events
- Homozygotes (TT) on MD had significant improvement in fasting glucose (FG) and lipids; the MD also negated their increased stroke risk

Corella, D., et. al. (2013). Mediterranean Diet Reduces the Adverse Effect of the TCF7L2-rs7903146 Polymorphism on Cardiovascular Risk Factors and Stroke Incidence: A randomized controlled trial in a high-cardiovascular-risk population.

Diabetes Care. doi: 10.2337/dc13-0955

# Mediterranean Diet Mitigates Stroke Risk Generated by TCF7L2 Gene



Cumulative stroke free-survival by TCF7L2-rs7903146 genotypes in the control

group (A) (1 ellez, 291) and 113the MedD fet intervention groups (B) Copyright Bale/Doneen Paradigm

# Cinnamon Reuces Glucose and Improves Lipids

- Meta-analysis of 10 RCTs; 543 diabetic pts; cinnamon 120 mg/d to 6 g/d for 4 to 18 wks
- Cinnamon showed statistically significant decrease in levels of fasting plasma glucose, TC, LDL-C, TG and increased HDL-C.

Allen, R. W., et. al. (2013). Cinnamon Use in Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis. *Ann Fam Med*, 11(5), 452-459.



# EPA and DHA levels Predictability of risk for ACS

Analyzed whole blood of 94 ACS patients and 94 age-gender matched controls

Omega 3 associations with ACS were made (adjusted for smoking, BMI, DM, lipids, hx MI or revascularization)

EPA and DHA content was 29% lower in ACS group vs control  $(1.7 \pm 1.9\% \text{ vs } 2.4 \pm 1.4\%, \text{ p} < 0.0001)$ 

Low blood levels of EPA and DHA is an independent predictor of increased risk for ACS

W. Harris, K. Read, et al. Am J. Cardiology 8.31.2007;99:154-158



### Fish Consumption Reduces Stroke Risk

- RR for CVD with long chain omega 3 fatty acids measured as circulating biomarkers and self reported dietary exposures were 1.04 (95%CI-0.90 to 1.20) and 0.90 (0.80 to 1.01), respectively
- The beneficial effect of fish intake on cerebrovascular risk is likely mediated through the interplay of a wide range of nutrients abundant in fish.
- The lack of assoc. with risk reduction for long chain omega 3 fatty acids was consistent in primary or secondary prevention
- Findings suggest that single nutrients may have limited effects on chronic disease outside of their original food sources.

Chowdhury, R., et. al., BMJ 10/30/2012;345:e6698 doi: 10.1136/bmj.e6698


### Dark Chocolate Mitigates the Negative Arterial Effects of Hyperglycemia

- 12 healthy young adults; mean age 28; treated with 100mg dark flavanol rich dark chocolate & flavanol free white chocolate for 3 days with 7 day wash out in-between.
- At end of each treatment phase subjects underwent OGTT and endothelial function and oxidative tests were performed.

Grassi, D., et. al. *Hypertension. 8/2012;60:*00-00 DOI: 10.1161/HYPERTENSIONAHA.112.193995



#### Coffee can Reduce Risk DM



The Relationship Between Coffee Consumption and Subsequent Type 2 Diabetes Mellitus in Different Categories of Coffee Consumption

O'Keefe, J. H., Lavie, C. J. (2013). Effects of Habitual Coffee Consumption on Cardiometabolic Disease, Cardiovascular Health, and All-cause Mortality. *J Am Coll Cardiol*. doi: 10.1016/j.jacc.2013.06.035

### Coffee May Increase the Risk of DM?!

1,180 stage 1 BP non-DM pts; 18-45 yo; 639 CYP1A2 (caffeine) genotyping; followed 6 yrs.

58% were slow metabolizers of caffeine

24% developed pre-diabetes defined by FBG

Dr Lucio Mos 'results from the HARVEST study' presented at ESC Congress Sept. 2, 2014

### Coffee May Increase the Risk of DM?!

The risk of prediabetes associated with coffee intake was increased only in slow caffeine metabolizers.

HR for >3 cups/d -2.78 (95% CI,1.32-5.88) p=0.0076

Carriers of the slow \*1F allele (slow caffeine metabolizers) should abstain from drinking caffeinated coffee.

Dr Lucio Mos 'results from the HARVEST study' presented at ESC Congress Sept. 2, 2014

### Take Back to the Trenches

Consider genetic testing for all patients

Tests to arguably get on everyone:
 9p21, apo E, KIF6

Tests that are useful in certain patients:
 4q25, CYP2C19, Hp

If testing for MTHFR, realize the 'high risk' genotype (TT) is actually 'low risk' for CVD



## Upcoming Presentations







### My Last Chat of 2014

#### Congratulations Again to Dr. Amy Lynn Doneen!!!!









### **Upcoming Presentations**

11/14/14 - Brad speaking all day at DISH meeting – Brentwood, TN.

11/17/14- Amy giving Key Note Address at 2nd International Conference on Nursing & Healthcare -Chicago, III.

12/1/14 - Brad speaking at NY Dental Society Meeting – NY,NY.

1/9-10/15- Amy and Brad giving BDM training at TT SON.

2/13/15- Brad speaking at Second Annual Private Wealth Summit – Phoenix, AR

2/20-21/15- BDM Preceptorship in LV, NV.



# Getting Close to Announcing a CEO for IOA!!



501c3 status

Mission: to advance the science of arteriology to the point every person has the opportunity to live out their life free of significant arterial disease.



## Open for Discussion

